Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Biotechnology

Healthcare
$119.04 +3.57%

+$3.42 today

Market cap
$8.25B
Beta
1.92
P/E (TTM)
-33.3
EPS (TTM)
-$2.98
52W Low $60.80High $122.20

Volume 2.01M

Average 0.81M

RYTM Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Rhythm Pharmaceuticals, Inc.NASDAQ: RYTM

Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026

Cost of revenue growth accelerates

Q3 FY2026 cost of revenue of $12.17M rose 121.2% year over year, ahead of the +78.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 36.2% from the prior quarter. Over 3 fiscal years it compounded at +109.1% a year.

Context

  • Cost of revenue amounted to 10.3% of revenue in FY2025, unchanged from a year earlier.
  • Cost of revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +121.2% holds above the trailing-twelve-month pace of +78.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$12.17M+36.2% QoQ
Last fiscal yearDec 2025
$19.49M+45.8% YoY
LTMSep 2026
$33.06M+78.9% YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+121.2%——
1 year+45.8%——
3-year CAGR+109.1%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2025
19.49M USD
Year-over-year change
+45.8%
4-year CAGR
+138.8%

Cost of Revenue vs competitors

How RYTM compares with its peers on the latest reported figures

  • RYTM's LTM Sep 2026 cost of revenue of $33.06M is the 2nd highest of the 11 companies compared; the peer median is $314.5K.
  • Its year-over-year change of +78.9% is the 2nd highest of 4, against a peer median of +24.0%.
  • Cost of revenue amounts to 11.8% of revenue for RYTM, versus a peer median of 0.6%.
RYTM Competitors Peer median
Cost of Revenue for RYTM and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$206.11B +35566.9%+13.6%20.1%
RYTMRhythm Pharmaceuticals, Inc.LTM Sep 2026$33.06M +78.9%+109.1%11.8%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$1.59M ——8.0%
GPCRStructure Therapeutics Inc.LTM Jun 2026$1.22M ———
BMEABiomea Fusion, Inc.LTM Mar 2026$593K ———
SEPNSepterna, Inc.LTM Sep 2026$421K ——0.4%
VKTXViking Therapeutics, Inc.LTM Jun 2026$208K ———
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$124K +24.0%——
BIOABioAge Labs, Inc.LTM Mar 2026$63K ——0.6%
PTNPalatin Technologies, Inc.LTM Mar 2026$31.34K -99.1%—0.2%
BLTEBelite Bio, IncLTM Sep 2026$0 ———
Peer median (excluding RYTM) $314.5K+24.0%+13.6%0.6%

Competitors are the stored peer set for RYTM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.15M23.64M77.43M130.13M189.76M
Cost of Revenue599K2.13M9.3M13.37M19.49M
Gross Profit2.56M21.51M68.13M116.76M170.27M
Gross Margin81.0%91.0%88.0%89.7%89.7%
Research & Development104.13M108.63M134.95M237.96M167.34M
Selling, General & Admin68.49M92.03M117.53M144.3M194.94M
Operating Expenses172.61M200.66M252.48M382.26M362.28M
Depreciation & Amortization1.16M1.67M1.76M1.56M1.34M
EBITDA(68.45M)(174.25M)(168.46M)(238.09M)(174.12M)
EBITDA Margin-2170.4%-737.1%-217.6%-183.0%-91.8%
Operating Income(170.06M)(179.16M)(184.36M)(265.5M)(192.02M)
Operating Margin-5391.9%-757.9%-238.1%-204.0%-101.2%
Interest Income447K4.03M13.95M14.71M15.29M
Interest Expense05.2M13.89M20.6M20.58M
Other Income / Expenses100.45M(1.96M)243K5.25M(4.03M)
Income Before Tax(69.61M)(181.12M)(184.11M)(260.26M)(196.04M)
Pre-Tax Margin-2207.1%-766.2%-237.8%-200.0%-103.3%
Income Tax Expense00564K346K497K
Net Income(69.61M)(181.12M)(184.68M)(260.6M)(196.54M)
Net Margin-2207.1%-766.2%-238.5%-200.3%-103.6%
EPS (Basic)(1.37)(3.51)(3.20)(4.34)(3.11)
EPS (Diluted)(1.37)(3.51)(3.20)(4.34)(3.11)
Weighted Avg Shares49.6M52.12M57.67M61M64.98M
Weighted Avg Shares (Diluted)49.6M52.12M57.67M61M64.98M

Rhythm Pharmaceuticals, Inc.

NASDAQ:RYTM

Intrinsic Alpha fair value

Locked

Current Price

$119.04

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.